A	O
Cyclin	B:C2718191
D2	I:C2718191
-	O
derived	O
peptide	B:C0030956
acts	O
on	O
specific	O
cell	B:C1516337
cycle	I:C1516337
phases	I:C1516337
by	O
activating	O
ERK1	B:C0600388
/	I:C0600388
2	I:C0600388
to	O
cause	B:C0007465
the	I:C0007465
death	I:C0007465
of	O
breast	B:C1512505
cancer	I:C1512505
cells	I:C1512505
Protein	B:C0597304
degradation	I:C0597304
by	O
the	O
proteasome	B:C1752727
generates	O
functional	O
intracellular	B:C0178719
peptides	B:C0030956
.	O

Pep5	B:C0030956
,	O
a	O
peptide	B:C0030956
derived	O
from	O
Cyclin	B:C2718191
D2	I:C2718191
,	O
induces	O
cell	B:C0007587
death	I:C0007587
in	O
tumor	B:C0085983
cell	I:C0085983
lines	I:C0085983
and	O
reduces	O
the	O
volume	O
of	O
rat	B:C0034693
C6	B:C0017636
glioblastoma	I:C0017636
tumors	I:C0017636
in	B:C1515655
vivo	I:C1515655
.	O

Here	O
,	O
we	O
chose	O
the	O
human	B:C3898556
MDA	I:C3898556
-	I:C3898556
MB	I:C3898556
-	I:C3898556
231	I:C3898556
breast	B:C1512505
cancer	I:C1512505
cells	I:C1512505
to	O
evaluate	B:C0220825
the	O
mechanism	B:C1708951
of	I:C1708951
cell	I:C1708951
death	I:C1708951
induced	O
by	O
pep5	B:C0030956
in	O
different	O
phases	B:C1516337
of	I:C1516337
the	I:C1516337
cell	I:C1516337
cycle	I:C1516337
.	O

Fluorescently	B:C0079367
labeled	I:C0079367
pep5	B:C0030956
,	O
monitored	O
by	O
real	B:C0242842
time	I:C0242842
confocal	I:C0242842
microscopy	I:C0242842
,	O
entered	O
the	O
MDA	B:C3898556
-	I:C3898556
MB	I:C3898556
-	I:C3898556
231	I:C3898556
cells	B:C1512505
3	O
min	O
after	O
application	O
and	O
localized	B:C0392752
to	O
the	O
nucleus	B:C0007610
and	O
cytoplasm	B:C0010834
.	O

Pep5	B:C0030956
-	O
induced	O
cell	B:C0007587
death	I:C0007587
was	O
increased	O
when	O
the	O
MDA	B:C3898556
-	I:C3898556
MB	I:C3898556
-	I:C3898556
231	I:C3898556
cell	B:C1512505
population	I:C1512505
was	O
arrested	O
at	O
the	O
G1/S	B:C1517341
transition	I:C1517341
or	O
in	O
S	O
phase	O
compared	O
to	O
asynchronous	O
cells	B:C0007634
.	O

Pep5	B:C0030956
induced	O
permanent	O
extracellular	B:C0600388
signal	I:C0600388
-	I:C0600388
regulated	I:C0600388
kinase	I:C0600388
(	O
ERK1/	B:C0600388
2	I:C0600388
)	O
phosphorylation	B:C0031715
in	O
MDA	B:C3898556
-	I:C3898556
MB	I:C3898556
-	I:C3898556
231	I:C3898556
cells	B:C1512505
synchronized	O
in	O
G1/	B:C1517341
S	I:C1517341
or	O
S	O
phase	O
.	O

Affinity	B:C0008551
chromatography	I:C0008551
followed	O
by	O
mass	B:C0037813
spectrometry	I:C0037813
identified	O
CLIC1	B:C1314856
and	O
Plectin	B:C0071277
as	O
the	O
only	O
two	O
proteins	B:C0033684
that	O
interacted	O
with	O
pep5	B:C0030956
in	O
both	O
asynchronous	O
and	O
synchronized	O
MDA	B:C3898556
-	I:C3898556
MB	I:C3898556
-	I:C3898556
231	I:C3898556
cells	B:C1512505
.	O

These	O
interactions	O
could	O
explain	O
the	O
long	O
-	O
lasting	O
ERK1	B:C0600388
/	I:C0600388
2	I:C0600388
phosphorylation	B:C0031715
and	O
the	O
cytoskeleton	B:C0010853
perturbations	O
in	O
the	O
MDA	B:C3898556
-	I:C3898556
MB	I:C3898556
-	I:C3898556
231	I:C3898556
cells	B:C1512505
,	O
in	O
which	O
the	O
stress	B:C0887904
fibers	I:C0887904
'	O
integrity	O
is	O
affected	O
by	O
pep5	B:C0030956
treatments	B:C0087111
.	O

These	O
data	O
suggest	O
that	O
pep5	B:C0030956
has	O
potential	O
therapeutic	O
properties	O
for	O
treating	B:C0087111
specific	O
types	O
of	O
cancers	B:C0006826
,	O
such	O
as	O
breast	B:C1512505
cancer	I:C1512505
cells	I:C1512505
.	O

Pep5	B:C0030956
,	O
a	O
natural	O
intracellular	B:C0178719
peptide	B:C0030956
formed	O
by	O
the	O
degradation	B:C0597304
of	I:C0597304
Cyclin	I:C0597304
D2	I:C0597304
through	O
the	O
ubiquitin	B:C1523807
-	I:C1523807
proteasome	I:C1523807
system	I:C1523807
,	O
induces	O
cell	B:C0007587
death	I:C0007587
when	O
reintroduced	O
into	O
MDA	B:C3898556
-	I:C3898556
MB	I:C3898556
-	I:C3898556
231	I:C3898556
breast	B:C1512505
cancer	I:C1512505
cells	I:C1512505
,	O
which	O
express	O
low	O
levels	O
of	O
Cyclin	B:C2718191
D2	I:C2718191
,	O
specifically	O
in	O
G1	B:C1517341
/	I:C1517341
S	I:C1517341
arrested	B:C0007634
cells	I:C0007634
or	O
in	O
cells	B:C0007634
that	O
are	O
passing	O
through	O
S	O
phase	O
.	O

Under	O
these	O
conditions	O
,	O
pep5	B:C0030956
is	O
able	O
to	O
interact	O
with	O
different	O
intracellular	B:C0178719
proteins	B:C0033684
,	O
primarily	O
cytoskeleton	B:C0010853
and	O
proteasome	B:C0208355
components	I:C0208355
,	O
which	O
can	O
lead	O
to	O
cellular	B:C0162638
apoptosis	I:C0162638
.	O

Together	O
,	O
our	O
data	O
suggest	O
that	O
pep5	B:C0030956
is	O
an	O
intracellular	B:C0178719
peptide	B:C0030956
with	O
therapeutic	O
potential	O
for	O
treating	B:C0087111
specific	O
types	O
of	O
tumors	B:C0027651
with	O
low	O
expression	B:C1171362
of	O
Cyclin	B:C2718191
D2	I:C2718191
by	O
inhibiting	O
cell	B:C0596290
proliferation	I:C0596290
.	O

